Abstract
The oncolytic viruses now hold a promise of new therapeutic strategy for cancer. Its concept has inspired a wave of commercial research and development activities for the products of this category in China since 1998. The first commercialized oncolytic virus product in the world, Oncorine (H101), developed by Shanghai Sunway Biotech Co., Ltd since 1999, was approved by Chinese SFDA in November, 2005 for nasopharyngeal carcinoma in combination with chemotherapy after the phase III clinical trial, and finally acquired GMP certificate in August, 2006. This review introduces how Oncorine was successfully developed in China, and how the Chinese market responded after it was launched into the market in 2006.
Keywords: Oncorine, oncolytic virus, nasopharyngeal carcinoma, cancer, chemotherapy, virotherapy.
Current Cancer Drug Targets
Title:Oncorine, the World First Oncolytic Virus Medicine and its Update in China
Volume: 18 Issue: 2
Author(s): Min Liang*
Affiliation:
- Totbiopharm Shanghai R&D Center, 781 Cailun Road, Shanghai, 201203,China
Keywords: Oncorine, oncolytic virus, nasopharyngeal carcinoma, cancer, chemotherapy, virotherapy.
Abstract: The oncolytic viruses now hold a promise of new therapeutic strategy for cancer. Its concept has inspired a wave of commercial research and development activities for the products of this category in China since 1998. The first commercialized oncolytic virus product in the world, Oncorine (H101), developed by Shanghai Sunway Biotech Co., Ltd since 1999, was approved by Chinese SFDA in November, 2005 for nasopharyngeal carcinoma in combination with chemotherapy after the phase III clinical trial, and finally acquired GMP certificate in August, 2006. This review introduces how Oncorine was successfully developed in China, and how the Chinese market responded after it was launched into the market in 2006.
Export Options
About this article
Cite this article as:
Liang Min *, Oncorine, the World First Oncolytic Virus Medicine and its Update in China, Current Cancer Drug Targets 2018; 18 (2) . https://dx.doi.org/10.2174/1568009618666171129221503
DOI https://dx.doi.org/10.2174/1568009618666171129221503 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization
Anti-Cancer Agents in Medicinal Chemistry Humoral and Mechanical Cross-Talk in the Vasculature: Perspectives in Vascular Disease
Vascular Disease Prevention (Discontinued) Oxidative Stress and Cancer: The Role of Nrf2
Current Cancer Drug Targets Emerging Immunotargets in Bladder Cancer
Current Drug Targets Nano Drug Delivery in Treatment of Oral Cancer, A Review of the Literature
Current Drug Targets Anticancer Activity of Organogallium(III) Complexes in Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Radiation Protection and Mitigation by Natural Antioxidants and Flavonoids: Implications to Radiotherapy and Radiation Disasters
Current Molecular Pharmacology Advances in Exploring the Role of Micrornas in Inflammatory Bowel Disease
MicroRNA Transactivation of EGFR by G Protein-Coupled Receptor in the Pathophysiology of Intimal Hyperplasia
Current Vascular Pharmacology Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer
Current Medicinal Chemistry From the Sea to Anticancer Therapy
Current Medicinal Chemistry Patent Selections:
Recent Patents on Biomarkers Personalization of Targeted Therapy in Advanced Thyroid Cancer
Current Genomics Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Small Molecule Aurora Kinases Inhibitors
Current Medicinal Chemistry Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Current View on the Mechanism of Action of Perifosine in Cancer
Anti-Cancer Agents in Medicinal Chemistry Exploiting Novel Cell Cycle Targets in the Development of Anticancer Agents
Current Cancer Drug Targets